CRESCENT BIOPHARMA, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
CRESCENT BIOPHARMA, INC. (CBIO) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$2.34 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2025-05-14
- CRESCENT BIOPHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-03-31 was -$2.34M.
- CRESCENT BIOPHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-12-31 was -$7.22M.
- CRESCENT BIOPHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-09-30 was -$9.82M.
- CRESCENT BIOPHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-06-30 was -$10.10M.
- CRESCENT BIOPHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$37.88M.
- CRESCENT BIOPHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$36.90M.
- CRESCENT BIOPHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$46.69M.
- CRESCENT BIOPHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$63.43M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2025-03-31 | -$2.34M 10-Q · filed 2025-05-14 | -$9.57M derived: sum of 2 quarters · filed 2025-05-14 | -$19.39M derived: sum of 3 quarters · filed 2025-05-14 | -$29.49M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | -$7.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$17.05M derived: sum of 2 quarters · filed 2025-02-13 | -$27.14M derived: sum of 3 quarters · filed 2025-02-13 | -$37.88M 10-K · filed 2025-02-13 |
| 2024-09-30 | -$9.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$19.92M derived: sum of 2 quarters · filed 2024-11-13 | -$30.66M 10-Q · filed 2024-11-13 | -$39.74M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-06-30 | -$10.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$20.83M 10-Q · filed 2024-08-08 | -$29.91M derived: sum of 3 quarters · filed 2025-05-14 | -$39.11M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-03-31 | -$10.74M 10-Q · filed 2025-05-14 | -$19.82M derived: sum of 2 quarters · filed 2025-05-14 | -$29.02M derived: sum of 3 quarters · filed 2025-05-14 | -$37.28M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$9.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$18.28M derived: sum of 2 quarters · filed 2025-02-13 | -$26.54M derived: sum of 3 quarters · filed 2025-02-13 | -$36.90M 10-K · filed 2025-02-13 |
| 2023-09-30 | -$9.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$17.46M derived: sum of 2 quarters · filed 2024-11-13 | -$27.82M 10-Q · filed 2024-11-13 | -$38.07M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$8.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$18.62M 10-Q · filed 2024-08-08 | -$28.86M derived: sum of 3 quarters · filed 2024-08-08 | -$37.39M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$10.36M 10-Q · filed 2024-05-09 | -$20.60M derived: sum of 2 quarters · filed 2024-05-09 | -$29.13M derived: sum of 3 quarters · filed 2024-05-09 | -$42.40M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$10.24M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$18.77M derived: sum of 2 quarters · filed 2024-03-27 | -$32.04M derived: sum of 3 quarters · filed 2024-03-27 | -$46.69M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$8.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$21.79M derived: sum of 2 quarters · filed 2023-11-03 | -$36.44M 10-Q · filed 2023-11-03 | -$53.87M derived: sum of 4 quarters · filed 2024-03-27 |
| 2022-06-30 | -$13.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$27.92M 10-Q · filed 2023-08-02 | -$45.34M derived: sum of 3 quarters · filed 2024-03-27 | -$62.67M derived: sum of 4 quarters · filed 2024-03-27 |
| 2022-03-31 | -$14.65M 10-Q · filed 2023-05-03 | -$32.07M derived: sum of 2 quarters · filed 2024-03-27 | -$49.41M derived: sum of 3 quarters · filed 2024-03-27 | -$63.81M derived: sum of 4 quarters · filed 2024-03-27 |
| 2021-12-31 | -$17.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$34.75M derived: sum of 2 quarters · filed 2024-03-27 | -$49.15M derived: sum of 3 quarters · filed 2024-03-27 | -$63.43M 10-K · filed 2024-03-27 |
| 2021-09-30 | -$17.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$31.73M derived: sum of 2 quarters · filed 2022-11-09 | -$46.01M 10-Q · filed 2022-11-09 | -$61.57M derived: sum of 4 quarters · filed 2023-03-29 |
| 2021-06-30 | -$14.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$28.67M 10-Q · filed 2022-08-03 | -$44.24M derived: sum of 3 quarters · filed 2023-03-29 | -$57.96M derived: sum of 4 quarters · filed 2023-03-29 |
| 2021-03-31 | -$14.27M 10-Q · filed 2022-04-28 | -$29.84M derived: sum of 2 quarters · filed 2023-03-29 | -$43.56M derived: sum of 3 quarters · filed 2023-03-29 | -$57.64M derived: sum of 4 quarters · filed 2023-03-29 |
| 2020-12-31 | -$15.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$29.29M derived: sum of 2 quarters · filed 2023-03-29 | -$43.36M derived: sum of 3 quarters · filed 2023-03-29 | -$51.03M 10-K · filed 2023-03-29 |
| 2020-09-30 | -$13.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$27.80M derived: sum of 2 quarters · filed 2021-11-02 | -$35.46M 10-Q · filed 2021-11-02 | -$50.19M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | -$14.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$21.74M 10-Q · filed 2021-08-05 | -$36.47M derived: sum of 3 quarters · filed 2022-03-03 | -$49.72M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | -$7.66M 10-Q · filed 2021-05-03 | -$22.39M derived: sum of 2 quarters · filed 2022-03-03 | -$35.64M derived: sum of 3 quarters · filed 2022-03-03 | -$51.47M derived: sum of 4 quarters · filed 2022-03-03 |
| 2019-12-31 | -$14.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$27.98M derived: sum of 2 quarters · filed 2022-03-03 | -$43.81M derived: sum of 3 quarters · filed 2022-03-03 | -$57.89M 10-K · filed 2022-03-03 |
| 2019-09-30 | -$13.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$29.08M derived: sum of 2 quarters · filed 2020-11-06 | -$43.17M 10-Q · filed 2020-11-06 | -$57.07M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-06-30 | -$15.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | -$29.91M 10-Q · filed 2020-07-31 | -$43.82M derived: sum of 3 quarters · filed 2021-03-02 | -$55.40M derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-03-31 | -$14.08M 10-Q · filed 2020-05-01 | -$27.99M derived: sum of 2 quarters · filed 2021-03-02 | -$39.57M derived: sum of 3 quarters · filed 2021-03-02 | -$50.84M derived: sum of 4 quarters · filed 2021-03-02 |
| 2018-12-31 | -$13.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | -$25.48M derived: sum of 2 quarters · filed 2021-03-02 | -$36.76M derived: sum of 3 quarters · filed 2021-03-02 | -$48.27M 10-K · filed 2021-03-02 |
| 2018-09-30 | -$11.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$22.85M derived: sum of 2 quarters · filed 2019-11-07 | -$34.37M 10-Q · filed 2019-11-07 | -$43.62M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | -$11.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$22.79M 10-Q · filed 2019-08-01 | -$32.05M derived: sum of 3 quarters · filed 2020-02-28 | -$40.00M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | -$11.51M 10-Q · filed 2019-05-02 | -$20.77M derived: sum of 2 quarters · filed 2020-02-28 | -$28.72M derived: sum of 3 quarters · filed 2020-02-28 | -$36.86M derived: sum of 4 quarters · filed 2020-02-28 |
| 2017-12-31 | -$9.26M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$17.21M derived: sum of 2 quarters · filed 2020-02-28 | -$25.35M derived: sum of 3 quarters · filed 2020-02-28 | -$33.28M 10-K · filed 2020-02-28 |
| 2017-09-30 | -$7.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | -$16.09M derived: sum of 2 quarters · filed 2018-11-02 | -$24.02M 10-Q · filed 2018-11-02 | |
| 2017-06-30 | -$8.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$16.07M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | -$7.93M 10-Q · filed 2018-05-03 | |||
| 2016-12-31 | -$31.81M 10-K · filed 2019-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |